New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
07:04 EDTSNTASynta , QuantumLeap announce selection of Ganetespib for I-SPY2 TRIAL
Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative announced that Synta’s lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL. I-SPY 2 is a standing phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neo-adjuvant setting. Synta recently presented positive results from a single-arm multi-center Phase 2 proof-of-concept study, the ENCHANT-1 trial. ENCHANT-1 was designed to evaluate the clinical activity of single-agent ganetespib preceding standard first line treatment. Of four patients in the study’s HER2+ cohort evaluable for response by RECIST, three patients achieved an objective response, including one complete radiological response, and one patient achieved stable disease. Of 11 evaluable patients in the study’s TNBC cohort, two patients achieved a partial response and five patients achieved stable disease. Of these, one responding patient was adjudicated a clinical complete response, was restaged to operable and underwent a total mastectomy with curative intent.
News For SNTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SNTA

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use